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httpFamilial abdominal aortic aneurysm is associated
with more complications after endovascular
aneurysm repair
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Danielle Majoor-Krakauer, MD, PhD,c Ellen V. Rouwet, MD, PhD,a Robert J. Stolker, MD, PhD,b and
Hence J. M. Verhagen, MD, PhD,a Rotterdam, The Netherlands; and Lisbon, Portugal
Objective: A familial predisposition to abdominal aortic aneurysms (AAAs) is present in approximately one-ﬁfth of
patients. Nevertheless, the clinical implications of a positive family history are not known. We investigated the risk of
aneurysm-related complications after endovascular aneurysm repair (EVAR) for patients with and without a positive
family history of AAA.
Methods: Patients treated with EVAR for intact AAAs in the Erasmus University Medical Center between 2000 and 2012
were included in the study. Family history was obtained by written questionnaire. Familial AAA (fAAA) was deﬁned as
patients having at least one ﬁrst-degree relative affected with aortic aneurysm. The remaining patients were considered
sporadic AAA. Cardiovascular risk factors, aneurysm morphology (aneurysm neck, aneurysm sac, and iliac measure-
ments), and follow-up were obtained prospectively. The primary end point was complications after EVAR, a composite of
endoleaks, need for secondary interventions, aneurysm sac growth, acute limb ischemia, and postimplantation rupture.
Secondary end points were speciﬁc components of the primary end point (presence of endoleak, need for secondary
intervention, and aneurysm sac growth), aneurysm neck growth, and overall survival. Kaplan-Meier estimates for the
primary end point were calculated and compared using log-rank (Mantel-Cox) test of equality. A Cox-regression model
was used to calculate the independent risk of complications associated with fAAA.
Results: A total of 255 patients were included in the study (88.6% men; age 72 6 7 years, median follow-up 3.3 years;
interquartile range, 2.2-6.1). A total of 51 patients (20.0%) were classiﬁed as fAAA. Patients with fAAA were younger (69
vs 72 years; P [ .015) and were less likely to have ever smoked (58.8% vs 73.5%; P [ .039). Preoperative aneurysm
morphology was similar in both groups. Patients with fAAA had signiﬁcantly more complications after EVAR (35.3% vs
19.1%; P[ .013), with a twofold increased risk (adjusted hazard ratio, 2.1; 95% conﬁdence interval, 1.2-3.7). Secondary
interventions (39.2% vs 20.1%; P[ .004) and aneurysm sac growth (20.8% vs 9.5%; P[ .030) were the most important
elements accounting for the difference. Furthermore, a trend toward more type I endoleaks during follow-up was
observed (15.6% vs 7.4%; P [ .063) and no difference in overall survival.
Conclusions: The current study shows that patients with a familial form of AAA develop more aneurysm-related
complications after EVAR, despite similar AAA morphology at baseline. These ﬁndings suggest that patients with
fAAA form a speciﬁc subpopulation and create awareness for a possible increase in the risk of complications after
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://dx.doi.org/10.1016/j.jvs.2013.08.029Approximately 20% of the abdominal aortic aneurysm
(AAA) patients have a positive family history for aneurysms,
with a prevalence ranging largely from 6% to 35%, depend-
ing on ethnicity and method of data collection.1-4 This
suggests that in these families there is a genetic predisposi-
tion to AAA and that patients can be classiﬁed as familial
AAA (fAAA), whereas patients without a clear inherited
risk can be classiﬁed as sporadic AAA (spAAA). Despite
the apparent familial tendency toward AAA formation
and results from some genetic studies, the exact underlying
genetic defects and their contribution to the development,
growth, and severity of complications are unknown.5 The
molecular and clinical well-delineated genetic aortic aneu-
rysm syndromes, including Marfan, Loeys-Dietz, the
vascular Ehlers-Danlos syndrome, and defects in the
smooth muscle cell genes MYH11 and ACTA2, are mostly
associated with thoracic aortic aneurysms, but occasionally275
Fig 1. Flow diagram of patient inclusion. AAA, Abdominal aortic aneurysm; EVAR, endovascular aneurysm repair.
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most known syndromes, in AAA, there are recognized
defects both in the connective tissue components and in
cellular elements affecting all layers of the aortic wall.5
In the last decade, endovascular aneurysm repair
(EVAR) has proven to be a valid treatment modality for
AAA and the majority of elective patients are now treated
endovascularly.11 Generally, endovascular repair in patients
with known genetic aortic aneurysm syndromes is not
advised, since patients have a higher chance of complica-
tions.12,13 At present, little is known on clinical outcome
after EVAR for patients with an inherited risk for AAA,
and no data on aneurysm morphology of this particular
group are available to date. One may hypothesize that
AAA patients with a positive family history may develop
more seal and ﬁxation problems, and also postimplantation
sac growth because of inherited aortic wall defects.
Furthermore, differences in aneurysm morphology for
fAAA patients, if present, could also inﬂuence outcome.
In the present study, we evaluated aneurysm-related
complications after EVAR for patients with fAAA and
spAAA and explored possible differences in aneurysm
morphology in these groups.
METHODS
The study population was derived from a prospective
database including all EVAR procedures performed at theErasmus University Medical Center in Rotterdam, The
Netherlands. From January 2000 until March 2012, 473
patients were treated with EVAR at our institution. Exclu-
sion criteria for this study were isolated iliac artery aneu-
rysm, traumatic aneurysm, anastomotic aneurysm,
infectious aneurysm, and ruptured aneurysm. Between
2009 and 2012, all AAA patients at our institution were
contacted when visiting the outpatient clinic or by mail
and asked to ﬁll out a semistructured questionnaire to
collect personal data and family histories. Patients who
did not respond after one reminder were contacted and
interviewed by telephone (K.V.). In families with multiple
AAA patients, only one index patient (ie, ﬁrst family
member diagnosed with AAA) was included in the study.
Patients previously diagnosed with a genetic aortic aneu-
rysm syndrome (eg, Marfan, Loeys-Dietz, or vascular
Ehlers-Danlos syndrome) were excluded, but no speciﬁc
genetic testing was routinely performed. A ﬂow diagram
of patient inclusion is presented in Fig 1. The study
complied with the declaration of Helsinki and was
approved by the Institutional Review Board.
Questionnaire and classiﬁcation of familial AAA.
The questionnaire requested information on demographics
and the medical history of the index patient. Furthermore,
structured questions were included on the occurrence of
aortic aneurysms and cardiovascular disease for all known
relatives of the index patient. Patients were classiﬁed as
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siblings, or children) was reported to have an aortic aneu-
rysm.1 Patients who did not report a ﬁrst-degree relative
affected with AAA were classiﬁed as spAAA. Patients
reporting only second- or third-degree relatives were also
classiﬁed as spAAA because the reporting of medical
information of second- or third-degree relatives was
considered less reliable.
Image processing. All patients were preoperatively
assessed using computed tomography angiography (CTA)
and entered the institutional surveillance protocol that
included an early postoperative CTA (typically before
hospital discharge), a CTA at 6 months and 1 year, and
then CTA scans yearly after. Since 2007, the 6-month
examination has been waived, and CTA surveillance
replaced by duplex ultrasound (DUS) examinations in
selected patients considered a lower risk according to the
treating physician’s experience in concurrence with Clinical
Practice Guidelines of the European society for Vascular
Surgery. Also, DUS examinations or noncontrast CT scans
were performed as an alternative to CTA in patients with
impaired renal function.
CTA was performed according to standardized institu-
tional protocols. Morphologic analyses and measurements
were performed using dedicated software with center
lumen line (CLL) reconstruction (3Mensio, Vascular 4.2
software; 3Mensio Medical Imaging BV, Bilthoven, The
Netherlands). CLLs were semiautomatically constructed
and followed the center of the aortic and iliac permeable
lumen.
The preoperative, early (<30 days) postoperative, and
last follow-up CTA scans were analyzed in all patients. In
patients with complications after EVAR, all CTA scans
were analyzed.
Interobserver variability was previously assessed and
agreement was high for AAA diameter (R2 linear ¼
0.996), neck length (R2 linear ¼ 0.991), and neck diam-
eter (R2 linear ¼ 0.935).14
Deﬁnitions. Aneurysm related deﬁnitions used in the
study were derived from the reported standards for
EVAR and/or were previously described.11,14-17 Brieﬂy,
aneurysm and neck diameters were determined after CLL
reconstructions. Aneurysm neck length was deﬁned as the
length of the lowermost renal artery to the level where the
aortic diameter increases with at least 10%. Aneurysm
angulation (suprarenal and infrarenal) were deﬁned after
CLL reconstruction. Aneurysm neck thrombus and calci-
ﬁcation were deﬁned as having more than 25% of the cross-
sectional area of the neck being affected. Iliac stenosis was
deﬁned as having at least one focal stenosis in the one of
the iliac arteries. Iliac tortuosity was deﬁned as absent,
minor, or major by one experienced observer (F.B.G.)
using three-dimensional reconstruction. Iliac aneurysm was
deﬁned as having an iliac diameter over 3 cm measured
after CLL reconstructions. Aneurysm sac behavior and
proximal neck dilatation during follow-up were calculated
for patients with at least two suitable imaging surveillance
exams. Aneurysm neck growth was deﬁned as an increaseof $2 mm between the maximum neck diameter at
ﬁrst postoperative and last available CTA scan during
follow-up. Aneurysm sac growth was deﬁned as an increase
of in diameter $5 mm and aneurysm sac shrinkage as
a decrease in diameter $5 mm between the maximal
aneurysm diameter at ﬁrst postoperative and last available
imaging (ie, two available CTA scans or two available DUS
examinations) during follow-up.
End points. The primary study end point was freedom
from complications after EVAR. Complications after
EVAR was deﬁned as a composite of one of the following:
endoleak during follow-up (ie, type Ia, type Ib, type III, or
undetermined type endoleaks on postoperative examina-
tions), secondary intervention (ie, proximal stent/cuff,
limb extension, coil/glue embolization, open ligation of
collaterals, conversion to aorto-uni-iliac device, conversion
to open repair and relining), aneurysm sac growth, acute
limb ischemia, or postimplantation aneurysm rupture. Type
II endoleak was not included as a complication after EVAR
because we consider intervention for type II endoleak only
when in combination with aneurysm sac growth, which is
included as complication after EVAR.11 In case the primary
end point was met by multiple criteria, the date of the ﬁrst
event was considered for the purpose of survival analysis.
The secondary end points were individual components
of the primary end point (endoleak during follow-up,
secondary interventions, and aneurysm sac growth), aneu-
rysm neck growth, and overall survival after EVAR.
Clinical characteristics. The medical histories of the
patients were obtained from medical ﬁles. The demo-
graphic characteristics included sex and age. The cardiovas-
cular comorbidities included ischemic heart disease (history
of myocardial infarction, coronary revascularization, or
pathologic Q-waves on the electrocardiogram), cerebrovas-
cular disease (history of ischemic/hemorrhagic stroke or
transient ischemic attack), and cardiac arrhythmia. The
cardiovascular risk factors included kidney disease (esti-
mated glomerular ﬁltration rate <60 mL/min per
1.73 m2), diabetes mellitus (fasting plasma glucose
$7.0 mmol/L, nonfasting glucose $11.1 mmol/L, or
use of antidiabetic medication), hypertension (blood pres-
sure $140/90 mm Hg in nondiabetics, $130/
80 mmHg in diabetics, or use of antihypertensive medica-
tion), and chronic obstructive pulmonary disease (history
of chronic obstructive pulmonary disease or stage $1
according to the Global Initiative for Chronic Obstructive
Lung Disease classiﬁcation). Smoking status was obtained
and included current smoking and ever smoking (ie,
patients who are currently smoking OR patients with
a history of smoking). Prescription medications were re-
corded and included the use of statins, beta-blockers,
antiplatelets, and anticoagulant therapy.
Statistical analysis. Dichotomous data are described
as counts and percentages. Continuous variables are
described as mean (standard deviation) or median with
interquartile range (IQR) when not normally distributed.
Categorical data were analyzed with c2 tests and contin-
uous variables with analysis of variance or Kruskal-Wallis
Table I. Clinical characteristics at baseline
Variablea
Familial
AAA
(n ¼ 51)
Sporadic
AAA
(n ¼ 204) P value
Male sex 44 (86.3) 182 (89.2) .554
Age at diagnosis, years 69.3 6 8.1 72.1 6 7.1 .015
Age #65 years at diagnosis 14 (27.5) 31 (15.2) .040
Cardiovascular comorbidities
Ischemic heart disease 20 (39.2) 72 (35.3) .619
Cerebrovascular disease 6 (11.8) 25 (12.3) .905
Cardiac arrhythmia 7 (13.7) 17 (8.3) .243
Cardiovascular risk factors
Kidney disease 8 (15.7) 51 (25.0) .186
Diabetes mellitus 10 (19.6) 39 (19.1) .961
Hypertension 31 (60.8) 138 (67.6) .285
COPD 18 (35.3) 83 (40.7) .435
Smoking e current 17 (33.3) 81 (39.7) .403
Smoking e ever 30 (58.8) 150 (73.5) .039
Medication
Statins 40 (78.4) 148 (72.5) .393
Beta-blockers 42 (82.4) 152 (74.5) .240
Antiplatelets 43 (84.3) 150 (73.5) .108
Anticoagulants 5 (9.8) 27 (13.2) .508
COPD, Chronic obstructive pulmonary disease.
aContinuous data are presented as the mean 6 standard deviation and
categorical data as number (%).
Table II. Aneurysm morphology at baseline
Variablea,b
Familial
AAA
(n ¼ 51)
Sporadic
AAA
(n ¼ 204) P value
Neck diameter, mm 26.2 6 4.2 25.4 6 3.5 .194
Neck length, mm 31.2 6 17.5 31.5 6 13.9 .982
AAA diameter, mm 61.6 6 12.8 60.3 6 13.3 .533
Aneurysm angulation
Suprarenal, degrees
of angulation
22.3 6 17.7 24.0 6 18.1 .723
Infrarenal, degrees
of angulation
37.5 6 20.3 40.6 6 24.8 .415
Neck thrombus 14 (27.5) 70 (34.3) .263
Neck calciﬁcation 11 (21.6) 50 (24.5) .558
Iliac stenosis 8 (15.7) 38 (18.6) .553
Iliac tortuosity 28 (54.9) 110 (53.9) .985
Iliac aneurysms 15 (29.4) 65 (31.9) .736
AAA, Abdominal aortic aneurysm; CTA, computed tomography
angiography
aContinuous data are presented as the mean 6 standard deviation and
categorical data as number (%).
bPreoperative CTA scans were available for 242 patients.
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used to assess the hazard ratio (HR), along with the 95%
conﬁdence interval, for complications after EVAR between
fAAA and spAAA. Variables entered into the multivariate
Cox regression model were selected on basis of univariable
signiﬁcant differences at baseline between fAAA and
spAAA (ie, age and ever smoking). Kaplan-Meier estimates
were calculated for freedom from complications after
EVAR. Estimates for fAAA and spAAA were compared
using log-rank (Mantel-Cox) test of equality. To assess
a possible selection bias, we tested for differences in
complications after EVAR, for included and excluded
patients of the complete EVAR database, using c2 tests.
For all tests, a P value <.05 (two-sided) was considered
signiﬁcant. All analyses were performed using IBM SPSS
Statistics v. 20.0 (SPSS Inc, Chicago, Ill).
RESULTS
A total of 373 patients were treated with EVAR for intact
degenerative aorto-iliac aneurysms (Fig 1). Since 84 patients
died before receiving the questionnaire and 34 patients did
not respond to the questionnaire and could not be reached,
the total study population consisted of 255 patients. No
patients were identiﬁed with a genetic aortic aneurysm
syndrome. The mean age of the population was 71.5
(67.4) years and 226 patients (88.6%) were of male sex.
Clinical characteristics and aneurysm morphology
at baseline. Of the 255 included patients, 51 (20.0%) had
at least one affected ﬁrst-degree relative and were classiﬁed
as fAAA. The remaining 204 patients (80.0%) had no
affected ﬁrst-degree relative and were classiﬁed as spAAA.
All clinical characteristics at baseline are presented inTable I. Patients with fAAA were younger compared with
spAAA patients (69 vs 72 years; P ¼ .015) and were less
likely to have ever smoked (58.8% vs 73.5%; P ¼ .039).
There were no differences in aneurysm morphology
between the two groups (Table II). Preoperative neck and
aneurysm diameter were similar, as well as the presence of
iliac stenosis, iliac tortuosity, and iliac aneurysms.
Complications after EVAR. The median duration of
follow-up was similar for fAAA and spAAA patients
(3.9 years [IQR, 2.4-6.9] and 3.3 years [IQR, 2.1-5.5];
P ¼ .163). During this period, a total of 57 patients
(22.4%) had complications after EVAR; 18 fAAA patients
and 39 spAAA patients (35.3% vs 19.1%; P ¼ .013;
Table III). Kaplan-Meier estimates for freedom of
complications after EVAR were signiﬁcantly different
between both groups, with a 5-year estimate of 51% in
fAAA and 74% in spAAA (P ¼.007; Fig 2).
A total of 19 patients (37.3% of fAAA) had two or
more affected relatives. Patients with two or more affected
relatives had more complications after EVAR compared
with those with only one affected relative (42.1% vs
31.2%, respectively), although it did not reach statistical
signiﬁcance (P ¼ .443)
Patients with fAAA had a 2.1-fold increased risk of
complications after EVAR compared with spAAA patients
after adjustment for age and ever smoking (HR, 2.1; 95%
conﬁdence interval [CI], 1.2-3.7; Table IV). Age (HR,
0.99; 95% CI, 0.95-1.02; P ¼ .405) and ever smoking
(HR, 0.84; 95% CI, 0.49-1.45; P ¼ .538) did not predict
for complications after EVAR in the multivariable model.
Endoleaks during follow-up. Patients with fAAA had
more endoleaks during follow-up (15.7% vs 8.8%),
although it did not reach statistical signiﬁcance (P ¼ .147).
The difference appeared to be caused mainly by more type
Ia and Ib endoleaks (15.6% vs 7.4%; P ¼ .063).
Table III. Complications after endovascular aneurysm
repair (EVAR)
Variablea
Familial
AAA
(n ¼ 51)
Sporadic
AAA
(n ¼ 204) P value
Complications after EVAR, patients 18 (35.3) 39 (19.1) .013
Endoleak during follow-up, events 8 (15.7) 18 (8.8) .147
Type Ia 5 9
Type Ib 3 6
Type III 0 1
Type undetermined 0 2
Secondary intervention 20 (39.2) 41 (20.1) .004
Proximal stent/cuff 4 10
Limb extension 5 18
Coil/glue embolization 2 2
Open ligation of collaterals 3 4
Conversion to AUI 1 0
Conversion to open repair 2 5
Relining 3 2
Aneurysm sac growthb 10 (20.8) 18 (9.5) .030
Acute limb ischemia 0 4 .313
Postimplantation aneurysm rupture 0 0 .
AAA, Abdominal aortic aneurysm; AUI, aorto-uni-iliac device; CTA,
computed tomography angiography; DUS, duplex ultrasound.
aCategorical data are presented as number (%).
bAneurysm sac measurements were available for 237 patients with $ two
postoperative imaging examinations (ie, two CTA scans or two DUS
examinations).
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with fAAA had a signiﬁcantly higher secondary inter-
vention rate after EVAR than spAAA patients (39.2%
vs 20.1%; P ¼ .004). Proximal stent/cuff, coil/glue embo-
lization, open ligation of collaterals, and relining were more
common in patients with fAAA. Detailed data regarding
elements of secondary interventions are presented in
Table III.
Aneurysm sac behavior and proximal neck dilata-
tion during follow-up. Aneurysm sac growth was more
common in patients with fAAA than those with spAAA
(20.8% vs 9.5%; P ¼ .030; Table V). Notably, this was
independent of type II endoleaks, which occurred in 13.7%
of the fAAA patients and 11.8% of the spAAA patients (P ¼
.713). Patients with fAAA also tended to have less aneu-
rysm sac shrinkage (47.9% vs 63.0%; P ¼ .057). There was
no difference in aneurysm neck growth, which occurred in
59.5% of the fAAA patients and 63.2% in patients with
spAAA (P ¼ .662).
Overall long-term survival. During follow-up, 41
patients died; seven (13.7%) in the fAAA group and 34
(16.7%) in the spAAA group (P ¼ .609).
Assessment of selection bias. As mentioned above,
no difference in survival was observed between the two
groups. However, we observed a difference in complica-
tions after EVAR for patients included and excluded
from analysis (22.4% vs 15.1%, respectively; P ¼ .046).
DISCUSSION
The main ﬁnding of the study was that patients
with fAAA have a twofold higher risk of developinganeurysm-related complications after EVAR than patients
with spAAA, despite similar AAA morphology. Although
Brewster et al showed several years ago a trend toward
more aneurysm-related mortality in patients with a history
of aneurysmal disease,18 this is the ﬁrst report focusing on
the association between family history and complications
after EVAR.
In this study, we chose not to include patients with iso-
lated iliac, traumatic, anastomotic, or infectious aneurysms
because they either have different EVAR related complica-
tion risk or have other pathophysiological mechanisms
leading to aneurysm formation compared with “typical”
AAA. In addition, we excluded the ruptured aneurysms
because they have a high rate of nonresponders because
of high mortality, which could be an important source of
bias. Also, the purpose of this study was primarily to deter-
mine the contribution of family history to preoperative risk
assessment and modiﬁcation, which is essentially directed at
elective (preventive) situations. For ruptured aneurysms,
family history of AAA is most likely not going to change
the immediate attitude, which is to offer a life-saving
procedure.
We found that 20% of our AAA population had a posi-
tive family history, which is similar to other studies report-
ing on the prevalence of fAAA.1,19-21 Furthermore,
patients with fAAA were younger and were less likely to
have a history of smoking compared with patients with
spAAA in our population. Previous studies similarly sug-
gested that fAAA patients are slightly younger but studies
on the effect of smoking are scarce.1,20,22
Since it is well known that adverse AAA morphology
may result in increased number of adjunctive procedures,23
and it is also known that some genetic aortic aneurysm
syndromes are associated with speciﬁc anatomic features
like arterial elongation and tortuosity,24-26 we determined
aneurysm morphology before stent implantation. Maxi-
mum AAA diameter and presence of iliac tortuosity or
stenosis were comparable between the two groups. Simi-
larly, aneurysm neck characteristics such as diameter,
length, angulation as well as the presence of thrombus
and calciﬁcation were not different for fAAA and spAAA
patients. Consequently, the observed disparities in compli-
cations cannot be attributed to morphologic differences
between the groups.
Secondary interventions and aneurysm sac growth were
the most important elements accounting for the difference
in the composite primary end point of complications after
EVAR. Although patients with fAAA also tended to have
more endoleaks, in particular proximal and distal type I
endoleaks, this difference failed to reach statistical signiﬁ-
cance because of limited patient numbers in the two
groups. Patients with fAAA displayed more aneurysm sac
growth, independent of the presence of type II endoleaks
and less aneurysm sac shrinkage than patients with spAAA.
It may be hypothesized that an intrinsic weakness of the
aortic wall results in more rapid progression of aneurysm
disease and contributes to a higher need for secondary
interventions in fAAA patients. These observations suggest
Fig 2. Kaplan-Meier estimates are shown for complications after endovascular aneurysm repair (EVAR) between
familial abdominal aortic aneurysm (AAA) (dashed red line) and sporadic AAA (solid blue line). fAAA, Familial AAA;
spAAA, sporadic AAA.
Table IV. Uni- and multivariable analysis for
complications after endovascular aneurysm repair
(EVAR)-associated with familial abdominal aortic
aneurysm (AAA)
Univariable Multivariablea
HR 95% CI P value HR 95% CI P value
Sporadic AAA Ref Ref
Familial AAA 2.15 1.22-3.81 .008 2.05 1.15-3.66 .015
CI, Conﬁdence interval; HR, hazard ratio.
aAdjusted for age and ever smoking.
Table V. Aneurysm sac behavior and proximal neck
dilatation during follow-up
Variablea Familial AAA Sporadic AAA P value
Aneurysm neck diameterb
Growth 25 (59.5) 103 (63.2) .662
Aneurysm sac diameterc
Growth 10 (20.8) 18 (9.5) .030
Stability 15 (31.2) 52 (27.5) .608
Shrinkage 23 (47.9) 119 (63.0) .057
AAA, Abdominal aortic aneurysm; CTA, computed tomography angio-
graphy; DUS, duplex ultrasound.
aCategorical data are presented as number (%).
bAneurysm neck measurements were available for 205 patients with $ two
postoperative CTA scans.
cAneurysm sac measurements were available for 237 patients with $ two
postoperative imaging examinations (ie, two available CTA scans or two
available DUS examinations).
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ders may underlie aneurysm formation in patients with
familial AAA.
Over the median follow-up period of 3 years, aneurysm
neck growth was quite common (about 60%) in both
groups. This high rate results from a low threshold deﬁni-
tion and is comparable to other reports on contemporary
stent grafts.27,28In patients with known connective tissue disorders,
endovascular therapies have been shown to result in
much higher failure rates due to rapid dilatation or dissec-
tion of the aorta and are generally unadvised.12,13
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alternative over open repair in patients with a positive
family history because most complications observed in
our study in fAAA patients could be treated with minimally
invasive techniques. Also, low morbidity and the early
survival advantage of EVAR appears to be unchanged in
the fAAA group. Although standard postoperative surveil-
lance is still recommended, our study should create aware-
ness for the fact that patients with fAAA may develop more
complications after EVAR. New prospective studies are
needed for clariﬁcation of our ﬁndings and should deter-
mine which postoperative surveillance program suits
fAAA patients best. Apart from the surveillance program,
all fAAA patients in our institute receive genetic counseling
to provide information on the hereditary of aortic aneu-
rysms and are offered screening for all ﬁrst-degree relatives.
There are several limitations that need to be consid-
ered. First, the single-center nature of this study limits
the generalization of the results. A second limitation is
the classiﬁcation of familial AAA based on self-reported
family history alone. The chance of having affected relatives
is lower in small families compared with large families. Also,
since objective screening of relatives was not performed,
under-reporting of fAAA is likely. Third, no systematic
molecular screening was performed for the known genetic
aortic aneurysm syndromes. However, since these
syndromes are rare causes for AAAs and generally present
at a younger age, their contribution to the study popula-
tion is probably negligible. In addition, the relative short
follow-up of 3.3 years should be taken into account
because it is known that endoleaks may develop in a later
stage. Long-term follow-up is therefore warranted. Lastly,
our study is also limited by its retrospective design, there-
fore, we evaluated possible selection bias. The mortality
of fAAA and spAAA patients was similar for both groups,
which suggests homogeneity between the two included
groups, but we observed small difference in complications
after EVAR for included and excluded patients. This was
probably explained by the fact that patients treated for
ruptured aneurysms died more frequently in the perioper-
ative period and consequently could not develop a compli-
cation. Also, patients with a small anastomotic aneurysm
treated with a covered stent are less likely to develop an
EVAR-related complication as deﬁned in the study. There-
fore, we believe that bias might be present due to the study
design but was minimized by the chosen inclusion criteria
and does not invalidate the main ﬁndings of the study.
In conclusion, the current study shows that patients
with a familial form of AAA develop more aneurysm-
related complications after EVAR, despite similar AAA
morphology at baseline. Although the limitations of this
study suggest caution in interpretation of the results, the
twofold higher aneurysm-related complication rate after
EVAR should create awareness for a possible incremental
risk in this subgroup. Our ﬁndings emphasize the need
for further research on genetic causes and underlying
molecular mechanisms of AAA.AUTHOR CONTRIBUTIONS
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